

GALLIMUNE 302 ND+IB+EDS

Water-in oil emulsion for injection

Not
authorised

- Newcastle disease virus, strain Ulster 2C, Inactivated
- Infectious bronchitis virus, type Massachusetts, strain M41, Inactivated
- Eggdrop syndrome-1976 virus, strain V127, Inactivated

Product identification

Medicine name:

GALLIMUNE 302 ND+IB+EDS Water-in oil emulsion for injection

Active substance:

Newcastle disease virus, strain Ulster 2C, Inactivated

Infectious bronchitis virus, type Massachusetts, strain M41, Inactivated

Eggdrop syndrome-1976 virus, strain V127, Inactivated

Target species:

Chicken (for reproduction)

Route of administration:

Intramuscular use

Product details

Active substance and strength:

Newcastle disease virus, strain Ulster 2C, Inactivated

10.00 log₁₀ haemagglutination inhibiting unit(s) / 0.30 millilitre(s)

Infectious bronchitis virus, type Massachusetts, strain M41, Inactivated

10.00 log₁₀ haemagglutination inhibiting unit(s) / 0.30 millilitre(s)

Eggdrop syndrome-1976 virus, strain V127, Inactivated

162.00 log₁₀ haemagglutination inhibiting unit(s) / 0.30 millilitre(s)

Pharmaceutical form:

Emulsion for injection

Withdrawal period by route of administration:

Intramuscular use:

-

Chicken (for reproduction)

- Egg. 0 day

- Meat and offal. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI01AA13

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Surrendered

Authorised in:

Luxembourg

Package description:

(ID2): 1 Box with 10 Bottle (PolyPropylene) with 150 millilitre(s) (1500 millilitre(s))

(ID1): 1 Box with 1 Bottle (PolyPropylene) with 150 millilitre(s) (150 millilitre(s))

(ID3): 1 Box with 1 Bottle (PolyPropylene) with 300 millilitre(s) (300 millilitre(s))

(ID4): 1 Box with 10 Bottle (PolyPropylene) with 300 millilitre(s) (3000 millilitre(s))

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)

Marketing authorisation holder:

Boehringer Ingelheim Animal Health Belgium S.A.

Marketing authorisation date:

23/02/2004

Manufacturing sites for batch release:

Boehringer Ingelheim Animal Health France

Responsible authority:

Ministere De La Sante Division De La Pharmacie Et Des Medicaments

Authorisation number:

V 344/04/12/0815

Date of authorisation status change:

23/02/2009

Reference member state:

Germany

Procedure number:

DE/V/0227/001

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents